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THE INCORPORATION OF GLYCINE-2·14C INTO URINARY URIC ACID IN NORMAL
AND PORPHYRIC HUMAN SUBJECTS*
N. R. PIMSTO, E, M.D., E. B. DOWDLE, M.D., M.R.C.P. AID L. EALES, M.D., FR.C.P., CS/RIUCT Renal Meta-
bolic Research Group, Department of Medicine, University of Cape Town
In 1953 Shemin and Russell ' showed that Il-aminolaevuli-
nic acid (ALA) could serve as a common metabolic pre-
cursor of porphyrins and purines, and so. suggested the
possibility of a relationsrup between punne and haem
biosynthesis. Subsequent observations have ~ ;engthened
this suggestion. Labbe et al.' and Talrnan et al.' showed
diminished synthesis of uric acid by chick embryos render-
ed porphyric with allyl-isopropyl-acetamide. Gajd?s and
Gajdos-Torok4 have reported inhibition of porphynn syn-
thesis by the addition of purine nucleotides and nucleo-
sides to the growth medium sustaining Rhodopsell~o­
monas spheroides. Beneficial therapeutic effects of punne
compounds on the clinical and biochemical mallifestations
of porphyria in animals and man hav~ bee.n ;epo~te~ b~
several authors.'" Drug:; such a orotIc aCid, ethiomne
and ailyl-isopropyl-acetamideU are porphyrinogenic and
all reduce hepatic ATP levels.
Relatively little work has been done on purine metabol-
ism in human porphyria. Ludwig" and Taxay13 reported
low blood uric-acid concentrations in acute human por-
phyria although their observations may be ~xp~cable on
the basis of renal loss of urate and haemodilution rather
than from decreased purine synthesis. In view of the
suggested inverse relationsrup between purine sy~thesis
and porphyrin synthesis, we have conducted a senes of
experiments in which glycine-2-"C was administered to
human volunteers with porphyria.
Glycine-2-14C may be incorporated into purines by one of
two pathways: (a) It may be incorporated as part. of the
intact glycine molecule into position 5 of the punne nu-
cleus (carbon atom 4 being derived from the carbo~Yl
carbon of glycine, and nitrogen atom 7 from the ammo
nitrogen of glycine), or (b) it may be incorporated into
the 5th carbon atom of ALA and thence into carbon
atoms 2 and 8 of the purine nucleus (Fig. I). If there were
defective synthesi$ of purines from ALA without con-
comitant impairment of incorporation of glycine into
positions 4, 5 and 7 of the purine nucleus, porphyric s~b­
jects should show diminished incorporatIOn. of ra~lO­
activity into carbon atoms 2 and 8 (C2 + ~) with relative-
ly normal incorporation of radioactivity .into ~arbon
atoms 4 a. d 5 (C4 + 5) following the admllllstratJOn of
glycine-2-14C. The specific activity ratio C4 + 5 : C2 + 8
should be correspondingly higher in urinary uric acid ex-
creted by porphyrics than by normal subjects.
MATERIALS NO METHODS
The experiments were performed with the informed con-
sent of 3 control ubjects (HJ., A.J. and A.M.), 3 patients
with symptomatic porphyria (A.A., B.P. and W.B.) and 5
patients with variegate porphyria (A.v.R., ·M. ., M.de J.,
Z.M. and CJ.). The 3 control subjects were free of any
di ease that could have affected purine or glycine meta-
bolism. The diagnosis of ymptomatic porphyria and acute
porphyria wa established by the usual laboratory cri-
'Date received: 3 September 196 .
Fig. 1. Diagrammatic representation of the purine nucleu
of the uric acid molecule. Uric acid (see text) was degraded
in such a manner as to allow separate radioassay of carbon
atoms 4 + 5 and 2 + 8.
teria. Relevant clinical and laboratory data are given 10
Table I.
At 8 a.m. on the first day of the experimental period
each subject received an intravenous injection of an ac-
curately weighed solution containing approximately 90 }Lc
(2 mg.) of glycine-2-"C. Twenty-four-hour urine ample
were collected daily for 2 weeks for measurement and
isolation of uric acid. Serum uric-acid concentration were
determined daily.
The concentration of uric acid in the erum and urine
was determined by the enzymatic spectrophotometric
method of Liddle et al." Uric acid wa i olated from the
urine by the method of Hawke et al." After isolation the
uric acid wa recrystallized twice by the method of Liddle
et al." and degraded as de cri bed by Korn'" to yield car-
bon atoms 4 and 5 as glyoxylate, and carbon atoms 2
and 8 as urea. The glyoxylate was isolated for radioassay
as the crystalline semicarbazone. The urea was degraded
with urease to carbon dioxide which wa i olated a
barium carbonate for radioassay.
The uric-acid crystals, glyoxylate emicarbazone crys-
tals and barium-carbonate powder were weighed accurate-
ly for radioa say into tared liquid scintillation vial and
suspended in a scintillator of the following composition:
2,5-diphenyloxazole (PPO) 0·3 G; 1,4-bis-2-(5 phenyloxa-
zole)-benzene (POPOP) 0·3 G; Cab-O-Sil (packard) 4 G;
toluene 1 litre. The amples were then counted on a
Packard Tri-Carb Liquid cintiJlation pectrometer. Pre-
liminary experiment indicated that there was no self-
TABLE I. SUMMARY Of RElEVA'T DATA RELATI 'G TO SUBJECTS RECEIVING GLYCINE-2-U c
Serum urate Urillary urate Doseo!
Age mg.fIOO ml. mg.{24hr glycine-2-14C
Subject Sex (Yrs) Diagnosis (range) (rallge) (d.p.m. X 10-")
H.J. M 48 Peripheral va cular disease. Renal function normal 6·0-7·0 458-625 181·8
A.J. M 23 Post-traumatic Brown-Sequard syndrome 4·5-6,2 200-500 186·2
A.M. M 32 Convalescent osteitis 2·8-4·4 500-709 199·6
AA M 46 Symptomatic porphyria 3·7-5·9 471-639 199·5
B.P. M 49 Symptomatic porphyria 4·1-4·5 449-795 203·4
W.B. M 36 Symptomatic porphyria 2,7-5·0 491-688 191'3
A.v.R. F 19 Variegate porphyria (remis ion) 3·4-4·1 363-665 197·6
M. F 31 Variegate porphyria (acute attack) 2'5-5·4 279-539 178·2
M. del. F 26 Variegate porphyria (acute attack) 3·3-5·9 240-583 195·2
Z.M. F 53 Variegate porphyria (acute attack) 4·8--8·6 288--527 192·0
C.l. F 37 Variegate porphyria (acute attack) 1·8-3·3 317-536 191·8
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Detailed figures for each individual are presented in
Table 11. As can be seen from these data, the patients
with symptomatic porphyria excreted a consistently higher
fraction of the do e of glycine-2-14C as uric acid. There
was no significant difference between normal subjects and
subjects with variegate porphyria in the excretion of gIy-
cine-2-14C a urinary uric acid.
Degradation of the uric-acid samples for eparate
radioassay of C4 + 5 and C2 + 8 showed a daily varia-
tion in C4 + 5 : C2 + 8 pecific activity ratio that dif-
fered in extent from subject to subject. Technical factors
were presumably responsible for part of the variation,
since it was wider in subjects where isolation of the urin-
ary uric acid proved difficult or where only small amounts
tomatic porphyria excreted 0'228% of the dose as uric
acid, 0·166% as C4 + 5, and 0'044% as C2 + 8. The
subject with variegate porphyria in remission excreted
0'167% as uric acid, 0·123% as C4 + 5, and 0·033% as
C2 + 8. Tbe 4 subjects with variegate porphyria in acute
attacks excreted 0·186% of the dose as uric acid, 0·113 %
as C4 + 5, and 0·028°~ of the dose as C2 + 8.
f) J' •. "
Fig. 3. Cumulative incorporation of radioactivity injected
as glycine-2-H C into urinary uric acid in patient W.B. with
symptomatic porphyria. Note the virtually constant rate
of cumulative incorporation for the duration of the study.
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Fio. 2. Specific activity of urinary uric acid and carbon
atoms 4 + 5 and 2 + 8 following approximately 90 /lC
of glycine-2-"C given intravenously to patient W.B. with
symptomatic porphyria. ote the rapid rise in specific
activity followed by an irregular plateau.
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absorption over the range of weights used in tbe counting
vials. Tbe counting rates were corrected to disintegra-
tions per minute by re-counting the amples following
addition of a known amount of standardized n-hexa-
decane-"C.
12
RESULTS
In all subjects radioactivity could be detected in the
urinary uric acid excreted during the first 24 hours. The
specific activity of the excreted uric acid rose to reach a
peak within the first 48 hours after administration of gly-
cine-2-"C, after which it declined slowly as an irregular
and fluctuating plateau. Since an approximately similar
fraction of the administered "C was excreted as urinary
uric acid each day for 2 weeks, the cumulative excretion
curve was linear in all subjects. The results of a typical
experiment are shown in Fig. 2 and 3.
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The 3 normal subjects excreted an average of 0·172%
of the dose as uric ac.d. 0 115 0 0 of the dose as C4 + 5, and
0·029% of tbe dose as C2 + 8. The 3 subjects with ymp-
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TABLE n. INCORPORATION OF GLYCI E-2-14c INTO URlNARY URIC
ACID I NORMAL A '0 PORPHYRIC HUMAN SUBJECTS
jects had a mean C4 + 5 : C2 + 8 ratio of 4·09 with
relatively little scatter. Mean ratios found in porphyric
subjects were 3·5 in symptomatic porphyria, and 4·02 in
variegate porphyria. There were clearly no significant dif-
ferences in this regard.
of uric acid were available for degradation. Apart from a
slight and inconsistent tendency for C4 + 5 : C2 + 8
[<ltios to be lower during the first 3 - 4 days of each ex-
pi:riment, no definite pattern of C4 + 5 : C2 + 8 ratio
c11ange with time emerged. The results of one experiment
stlOwing relatively little variation are shown diagrammati-
c,llly in Fig. 2. Mean C4 + 5 : C2 + 8 ratios for all sub-
jects with ranges are given in Table 11. The normal sub-
A.A. Symptomatic
porphyria 0·239 0·164 0·049 3·51
B.P. Symptomatic
porphyria 0·216 0'161 0·039 4·17
W.E. Symptomatic
porphyria 0·230 0·173 0·046 3·82
Mean 0·228 0·166 0·044
A.v. R. Variegate porphyria
(remission) 0'167 0·123 0·033 3·68
M. Variegate porphyria
(acute attack) 0·200 0·160 0·025 6·42
M. del. Variegate porphyria
(acute attack) 0·154 0·112 0·033 3·39
Z.M. Variegate porphyria
(acute attack) 0·127 0·065 0·019 3·31
C.l. Variegate porphyria
(acute attack) 0·262 0'116 0·034 3·30
Mean 0'186 0·113 0·028
SUMMARY
Glycine-2-"C was administered intravenously to 3 control sub-
jects, 3 subjects with symptomatic porphyria and 5 subjects with
variegate porphyria. Uric acid was isolated from daily urine
samples for 2 weeks thereafter and the radioactivity assayed in
the whole molecule and in carbon atoms 4 and 5, and 2 and 8
of the purine nucleus. There were no major differences in in-
corporation of radioactivity between normals and porphyrics.
It is concluded that there is no major defect in purine met-
abolism in this disorder.
This work was supported by Grant PHS AM-03997 from the
ational Institute of Arthritis and Metabolic Diseases, Public
Health Service, USA, and formed part of the programme of
the CSIR/ CT Renal Metabolic Research Group which is
would contribute to the appearance of early-labelled uric
acid in the urine. DNA and R A in hepatic,"'" mye-
loid"'" and lymphoid" tissues have different rates of turn-
over and they would be expected to contribute radio-
active uric acid to the urine when degraded at a later
stage after administration of an i otopic precursor. The
superimposition of several curves of urinary uric-acid
specific activity, each with a different time relationship,
could well explain the irregular 'plateau' appearance of
the uric-acid specific activity curve and the failure of urin-
ary uric-acid specific activity to fall off exponentially with
time following HC precursor administration.
Had there been any consistent aberration of purine syn-
thesis in porphyria affecting one particular nucleic-acid
pool, one might have expected a distortion of the uric-
acid specific activity plateau characteristic of the biologi-
cal Life of the nucleic acid involved. This was not found
in any of the subjects studied.
In normal subjects and those with variegate porphyria
the percentage of the dose of glycine-2-14C incorporated
into C4 + 5 and C2 + 8 over 2 weeks did not differ sig-
nificantly, indicating no major impairment of purine syn-
thesis in the patients with porphyria in remission or in
the acute phase. It should be noted, however, that no
attempt was made to estimate the size of the uric-acid pool
or the extent of faecal elimination of uric acid, so
that these values cannot be regarded as an accurate re-
flection of the synthesis of uric acid from glycine. In the
3 subjects with symptomatic porphyria increased incor-
poration of glycine-2-14C into urinary uric acid, C4 + 5
and C2 + 8 was noted. Since hyperuricaemia is not a
feature of this disorder, there is no reason to presume that
excessive synthesis of uric acid occurs in this disease. It
is more probable that hepatic excretion of urate in this
disorder where liver disease is invariably found is im-
paired and, as a consequence, a greater proportion of
total urate excreted is eliminated by the kidney.
The C4 + 5 : C2 + 8 specific activity ratios were simi-
lar in normal and porphyric subjects, indicating no selec-
tive defect in the synthesis of the ureido carbons of uric
acid from glycine-2-B C. This observation is in accord with
other studies from this laboratory" that failed to demon-
strate impairment in the utilization of ALA-5-C for purine
synthesis in porphyria.
It can, on the basis of these experimental data, there-
fore, be concluded that purine synthe i in porphyria is
normal. This conclusion is supported by the observations
of De Matteis et al.," who found unchanged liver purine
levels in experimental porphyria.
Ratio:
C4 + 5
Cl + 8 Cl + 8
0·035 3·91
0·033 4·04
0·020 4·32
0·029
Whole
molecule C4 + 5
0·210 0·137
0·187 0'124
0·119 0·084
0·172 0·115
Cumulative % dose excre-
ted as urinary uric acid in
14 days
Diagnosis
Control
Control
Control
Mean
S/lbiect
H.l.
A.l.
A.M.
DISCUSSION
Our finding of prompt labelling of urinary uric acid fol-
lowed by a fluctuating plateau of specific activity is simi-
lar to the experience of others!"" The early labelling of
uric acid in non-gouty subjects has been regarded by
Gutman and Yu" and Wyngaarden"" as an overflow 'by-
P'ISS' for the elimination of surplus inosine monophos-
phate and other ribonucleotides generated in excess of
body needs. This idea is supported by the observation by
Wyngaarden et al.'· of prompt and striking labelling by
isotopic glycine of urinary hypoxanthine in excess of that
of other purine bases. The specific activity curves of hypo-
x'lnthine and uric acid in the experiment described bore
a precursor-product relationship.
It is, however, also conceivable that the time of ap-
P~arance of labelled uric acid in the urine is related to the
bi.ological life of the labelled purines from which the uric
a<:id was derived. Messenger ribonucleic acid, for
e>;ample, with a half-life of approximately 4 - 8 hours"
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STUDIES ON HUMAN PLATELETS*
VI. STUDY OF PLATELET ABNORMAUTIES BY DE 'SlTY GRADIE T SEPARATION OF PLATELET
POPULATlONS
F. M. BOOYSE, t D. C. HOH AND M. E. RAFELSON; From the Department of Biochemistry, Presbyterian-St Luke's
Hospital and University of Illinois College of Medicine, Chicago, Illinois, USA
Normal human platelets generally range from 2 to 4 p. in
diameter. However, in a number of diseases with as-
sociated bleeding tendencies, platelets often appear large,
bizarre and amorphous, showing lack of granularity and
poor distinction between chromomere and hyalomere.'"
Electron-microscopic examination of these atypical plate-
lets shows distinct morphologic changes."· In addition,
various biochemical defects such as reduced glucose con-
sumption, decreased ATP content and a decrease or ab-
sence of a number of enzymes have been described in
these atypical platelets.'"
Although the platelet count may be within normal
limits in a given situation, platelet appearance and func-
tion may be grossly abnormal. Examination of the role of
qualitative platelet abnormalities in the pathogenesis of
some cases of haemostatic failure can and has provided
a means of detecting and interpreting some poorly under-
stood but important aspects of haemostasis and platelet
function. The evaluation of qualitative platelet defects
can, however, prove to be very tedious. The purpose of
this communication is to describe a rapid method of
monitoring and evaluating alterations in platelet mor-
phology which can be associated with bleeding tendencies.
Human platelets have been separated into 4 populations
on a sucrose density gradient.'oo" These populations have
been characterized under the electron-microscope"'" and
in terms of a number of biochemical parameters such as
protein synthetic activity, ATP production, enzyme
activity and aggregation properties."·N Based on the
known morphologic and biochemical properties of the
'Date received: 8 April 1969
tPresent address: Department of Biochemistry. Faculty of Agriculture.
University of Pretoria, Pretoria.
separated populations, it has become apparent that plate-
let density gradient patterns can provide a qualitative and
quantitative picture of the platelet populations present in
various clinical situations.
MATERIALS AND METHODS
Preparation of Platelets
Whole blood (2'5 - 5 ml.) containing anticoagulant (I
ml. formula A ACD for every 5 ml. whole blood) was
diluted with 22 ml. of isotonic saline-ACD solution (20
ml. isotonic saline plus 2 ml. ACD formula A solution).
Platelet-rich plasma (diluted) was obtained by centrifuga-
tion at 80 g for 35 minutes. The platelet-rich plasma was
removed and recentrifuged at 80 g for 15 minutes. Plate-
lets were pelleted by centrifugation at 1,100 g for 15
minutes. 0 leucocyte or RBC contamination could be
detected under the light microscope at this stage.
The platelet pellet was resuspended in 1·0 ml. of iso-
tonic saline-ACD solution (I ml. ACD formula A solu-
tion plus 5 ml. isotonic saline) and applied onto the su-
crose gradients in appropriate volumes. The amount of
blood required to obtain the platelet samples is dependent
on the platelet count. With a normal platelet count, 2·5
- 5 ml. of blood yields an adequate platelet pellet and
distribution pattern. With markedly increased or de-
creased platelet counts, proportionately smaller or larger
volumes of blood are required. All procedures were
carried out at 5°C.
C radient Preparation and Quantitafion of Separated Plate-
let Population
Gradients were prepared from solutions containing 30,
50, 55, 58·8 and 65% sucrose (w / v), 2 mM EDTA, 0'15
